Transaction · 0001549595-25-000026

Ring Christine

Ring Christine, CLO, reported an open-market or private sale at Nurix Therapeutics, Inc. involving 5660.000000 shares for an estimated $112885.87. Reported holdings after the transaction were 32638.000000 shares. The stored filing text includes a detected 10b5-1 reference.

Open-market sellSEC transaction code SCLO
NRIXNurix Therapeutics, Inc.
Filing timeFeb 04
Trade dateJan 31, 2025
Filing · SECView on SEC
InsiderProfile

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
—
Pre-filing
1mo ago1w ago1d ago
Returns since
7d30d90d180d1y

NRIX price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
NRIX since 2025-02-04Filed 577 days ago · 30 days of pre-filing context shaded
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0001549595-25-000026
Common Stock
Transaction date
Jan 31, 2025
Filed Feb 04, 2025, 01:03 AM · 4d delay
Shares
5.66k sh
$1.99k per share
Estimated value
-$11.2M
Computed from shares × price
Holdings after
32.6k sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $10.0MLarge $100M
Cluster Selling Direct Ownership Repeat Seller 10b5-1 Detected
-4score
Filing-only score

-4

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

Chief Legal Officer

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

  2. F2

    Represents the weighted average sale price. The lowest price at which shares were sold was $19.465 and the highest price at which shares were sold was $20.42. The Reporting Person undertakes to provid…

  3. F3

    The option vested as to 1/4 of the total shares on September 9, 2020, and then 1/48 of the total shares vested monthly thereafter until the option was fully vested on August 9, 2023.

Original filing · 0001549595-25-000026
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

NRIX